Darzalex performs well in Janssen's rare disease study

New data from Janssen supports the use of Genmab-developed drug Darzalex Faspro to treat the rare disease AL amyloidosis.

Photo: Joost Melis / Genmab / PR

On Wednesday, Johnson & Johnson-company Janssen Pharmaceuticals, which produces and sells Genmab's blockbuster drug Darzalex, announced positive trial results for the subcutaneous (under the skin) version of this drug for treating the rare disease amyloid light-chain (AL) amyloidosis.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs